Skip to main content

Table 8 Total treatment costs for with and without SEB scenarios in year 5

From: A budget impact analysis of the introduction of erythropoiesis stimulating agent subsequent entry biologics for the treatment of anemia of chronic kidney disease in Canada

Patient type (CKD stage) Treatments for anemia of CKD Year 5 total costs ($)
Without SEB With SEB
Stage III/IV Short acting ESA (SC) 41,530,100 26,014,455
Llong acting ESA (SC) 43,200,535 27,060,815
Epoetin SEB - 18,505,171
Stage V Short acting ESA (SC) 28,324,361 17,742,380
Long acting ESA (SC) 19,614,295 12,286,394
Short acting ESA (IV) 116,364,164 72,890,512
Long acting ESA (IV) 80,917,865 50,686,950
Epoetin SEB - 53,556,198
Total 329,951,320 278,742,875
  1. SEB = subsequent entry biologic; CKD = chronic kidney disease; ESA = erythropoiesis stimulating agents; SC = subcutaneous; IV = intravenous.